阿皮克萨班度和对患有脏病综合征的患者凝血的影响
Sarah Kelddal1,2, Erik L Grove3,4, Camilla L Duus5
1Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Kidney medicine
|December 3, 2025
概括
像阿皮克萨班这样的直接口服抗凝剂可能适用于性综合征 (NS) 患者. 尽管度较低,但apixaban在NS中表现出有效的抗凝剂作用和优异的血栓生成抑制,与dalteparin相比.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
- 血液学 血液学 血液学
背景情况:
- 静脉血栓塞栓症 (VTE) 是性综合征 (NS) 的一个重要并发症.
- 目前的指导方针建议在NS中使用华法林或低分子量肝素 (LMWH) 来预防VTE.
- 关于在NS患者中使用直接口服抗凝剂 (DOAC) 的数据有限.
研究的目的:
- 评估标准剂量阿皮克萨班在NS患者中的稳定状态度和抗凝剂作用.
- 为了比较阿皮克萨班与达尔特帕林在抑制NS中血栓生成方面的疗效.
主要方法:
- 一个开放的,单臂的临床试验,涉及成年患者与NS和健康的对照.
- 患有NS的患者接受了达尔特帕林,随后每天两次服用阿皮克萨班5毫克.
- 评估了阿皮克萨班平稳状态血度和血栓生成标志物.
主要成果:
- 与健康个体相比 (51μg/L) (P=0.02),NS患者的平均稳定状态apixaban水平较低 (35μg/L).
- 在稳定状态 (P=0.19) 的两组之间,内源性血栓激素潜力是可比的.
- 在NS患者中,阿皮克萨班比达尔特巴林更能抑制体内血栓生成标记物.
结论:
- 患有NS的患者表现出较低的阿皮克萨班度,但达到与健康个体相比的抗凝剂效果.
- 阿皮克萨班有效地抑制了血栓生成,在NS中表现优于达尔特帕林.
- 阿皮克萨班在瘤综合征中为血栓预防提供了潜在的替代方案.
更多相关视频
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
8.8K
05:44Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
1.0K
相关概念视频
01:24Nephrotic Syndrome I : Introduction
470
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
470
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:29Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
01:24Nephrotic Syndrome III : Nursing Management
271
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
271
01:26Nephrotic Syndrome II : Assessment and Medical Management
184
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
184
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241